Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
After watching this activity, participants should be better able to:
- Review the risks and benefits of gonadotropin-releasing hormone agonists and antagonists in the treatment of advanced prostate cancer
- Discuss strategies to promote equitable care and address disparities in prostate cancer treatment outcomes
- Evaluate ways to incorporate patient preferences and improve adherence to ADT in clinical practice
In this activity, an oncologist, a nurse and a urologist provide their insights on the risks and benefits of GnRH agonists and antagonists for the treatment of advanced prostate cancer, including the barriers to equitable care and the potential reasons for disparities in treatment outcomes, as well as how to improve adherence to ADT in clinical practice.
This activity is jointly provided by USF Health and touchIME. read more
Validated prostate cancer specialists, including medical oncologists, radiation oncologists, urologists and specialist nurses involved in the management of advanced prostate cancer.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Tanya Dorff discloses: Advisory board or panel fees from Astellas Pharma (relationship terminated), AstraZeneca, Bayer, Janssen and Sanofi (relationship terminated).
Ms Brenda Martone has no interests/relationships or affiliations to disclose in relation to this activity.
Dr Stephen Freedland discloses: Consultancy fees from Astellas Pharma, AstraZeneca, Bayer, Janssen, Merck, Myovant Sciences, Pfizer and Sanofi.
Gigi Jameel, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Holly Gilbert-Jones and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.75 contact hours may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.
This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.
Date of original release: 21 September 2023. Date credits expire: 21 September 2024.
If you have any questions regarding credit please contact firstname.lastname@example.org.
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancerThis activity is CE/CME accredited
PARP inhibitors in prostate cancer: New combinations, new possibilitiesThis activity is CE/CME accredited
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
Timothy A Yap, AACR 2018 – Advances in Precision Cancer Medicine
Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
Foreword – European Haematology, 2009;3(1):6
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out